CagriSema Research for Prediabetes
An evidence-based overview of research examining CagriSema in the context of prediabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
In the REDEFINE-1 trial of adults with overweight or obesity, CagriSema improved glycemic measures alongside substantial weight loss, with many participants who had prediabetes at baseline shifting toward normoglycemia. This suggests potential for diabetes prevention in high-risk populations.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. CagriSema may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.